LEADER 04418nam 22006135 450 001 9910300095803321 005 20200702044625.0 010 $a3-642-38404-8 024 7 $a10.1007/978-3-642-38404-2 035 $a(CKB)3710000000077802 035 $a(EBL)1592540 035 $a(SSID)ssj0001090690 035 $a(PQKBManifestationID)11631143 035 $a(PQKBTitleCode)TC0001090690 035 $a(PQKBWorkID)11024911 035 $a(PQKB)11748352 035 $a(MiAaPQ)EBC1592540 035 $a(DE-He213)978-3-642-38404-2 035 $a(PPN)176112545 035 $a(EXLCZ)993710000000077802 100 $a20131212d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aEpigenetic Therapy of Cancer $ePreclinical Models and Treatment Approaches /$fedited by Michael Lübbert, Peter A. Jones 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (332 p.) 300 $aDescription based upon print version of record. 311 $a3-642-38403-X 320 $aIncludes bibliographical references and index. 327 $aThe fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation -- Mouse models to study DNA methylation in cancer research -- Epigenetic regulation of normal hematopoietic development -- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies -- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches -- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins -- Epigenetic abnormalities in lung cancer -- Pharmacodynamic Responses to DNA Methyltransferase Inhibition -- Histone Methyltransferases: Opportunities in Cancer Drug Discovery -- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy -- Clinical Implications of Epigenetic Alterations in Lung Cancer -- Epigenetic disturbances in colorectal cancer -- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results. 330 $aThe growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail. 606 $aOncology   606 $aHematology 606 $aGene therapy 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aGene Therapy$3https://scigraph.springernature.com/ontologies/product-market-codes/B12020 615 0$aOncology  . 615 0$aHematology. 615 0$aGene therapy. 615 14$aOncology. 615 24$aHematology. 615 24$aGene Therapy. 676 $a616.994042695 702 $aLübbert$b Michael$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aJones$b Peter A$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300095803321 996 $aEpigenetic Therapy of Cancer$91523186 997 $aUNINA